Tilray has become the first Canadian licensed producer to legally import medical cannabis extract products into Germany for nationwide distribution through pharmacies.

Starting next week, Tilray’s cannabis extracts will be available in German pharmacies nationwide through partnerships with leading German pharmaceutical wholesaler NOWEDA and service provider Paesel + Lorei.

Tilray products available in Germany will include two varieties of cannabis oil containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Unlike dried cannabis flower, extracts are consumed orally without smoking or vaporizing.

Tilray’s import follows unanimous passage of the “Cannabis Act” by German lawmakers in March 2017. The new law permits medical cannabis for therapeutic purposes in treating conditions such as chronic pain, tumor pain, and multiple sclerosis, as well as the side effects of chemotherapy. To ensure access to treatment, patients with serious disorders may apply to have medical cannabis covered by their insurance provider.

Tilray’s expansion into the German market resulted from close collaboration with respected companies that have long histories operating in the country’s pharmaceutical industry. To distribute its products nationwide, Tilray has partnered with pharmaceutical wholesaler NOWEDA and service provider Paesel + Lorei.

Tilray is committed to advancing scientific knowledge of medical cannabis through collaboration with world-leading researchers around the globe, including in Germany. Speaking at events in Berlin and Dusseldorf, Tilray CEO Brendan Kennedy announced that the company is actively searching for research partners in Germany. “Our goal is to make Germany a global centre of excellence for cannabinoid research,” said Kennedy.

Currently, Tilray supplies clinical trials on two continents. In Canada, Tilray supplies trials at Toronto SickKids Hospital (pediatric epilepsy), the University of British Columbia (post-traumatic stress disorder), and McGill University Health Centre (chronic obstructive pulmonary disease). In Australia, Tilray has partnered with the University of Sydney and New South Wales Government to study medical cannabis and chemotherapy-induced nausea and vomiting.